Saturday 17 October 2026 Export ORMP’s income statement to Excel — free account

Oramed Pharmaceuticals Inc.

In the quarter to June 2026, revenue grew 193.3%, EPS grew 493.8% and free cash flow grew 94.3%, each against the same quarter a year earlier.

4.07 0.11 −2.63%

Follow ORMP

Alert me

Market cap: $173.9M
P/E: 1.0×
Fwd P/E: −9.7×
Dividend yield: 6.14%
F-score: n/a
Altman Z: 1.91
Beneish M: n/a
Dividend safety: 45/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.17

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	2	—	—	2

Insider Ownership 23.66%

Capital & Financial Ratios $m

Market Cap 173.87

Revenue 4.02

Net Income 174.86

Free Cash Flow (5.21)

Net Debt (50.61)

Current Ratio 4.98

Debt/Equity 0.00

P/E ratio 0.96

Fwd P/E (9.71)

P/S ratio 41.54

P/B ratio 0.53

Past 5Y EPS Growth —

This Y EPS Growth 246.51%

Next Y EPS Growth 50.00%

Next Y revenue growth (25.37%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 56.38%

10-year low 10-year high

P/B against its own 10 years 2.65%

10-year low 10-year high

EV/Sales against its own 10 years 46.27%

10-year low 10-year high

Dividends

Payout Ratio 0.06

Annual Dividend Rate 0.25

Annual Dividend Yield 6.14%

	total	individual payouts
2026	0.25	0.25
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	162	142	126	51
Receivables	—	—	—	1
Inventory	—	—	—	—
Other	—	—	—	—
	163	143	133	53

	2023	2024	2025	Q'26
Payables	2	5	7	9
ST’ Debt	—	—	—	—
Other	—	—	—	—
	53	6	19	11

Compound Annual Growth %

	10y	5y	3y
Sales	12.05%	(5.85%)	(9.55%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	26.37%	3.69%	9.74%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	2	—	—	—	2
’23	1	1	—	—	1
’22	—	—	1	1	3
’22	1	1	—	—	3
’21	—	—	1	—	1
’21	1	1	—	—	3

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	0	—	—	—
’25	(4)	(4)	(2)	0	(9)
’24	(1)	2	(7)	(2)	(8)
’23	(6)	(3)	(1)	(1)	(10)
’22	—	—	(2)	(8)	(28)
’22	(9)	(8)	—	—	(29)
’21	—	—	1	3	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	0	—	—	—
’25	(4)	(4)	(2)	0	(9)
’24	(1)	2	(7)	(2)	(8)
’23	(6)	(3)	(1)	(1)	(11)
’22	—	—	(2)	(8)	(28)
’22	(9)	(9)	—	—	(29)
’21	—	—	1	3	(11)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.91	1.84	—	—	—
’25	(0.19)	0.31	1.13	0.24	1.50
’24	0.04	0.22	(0.48)	(0.25)	(0.48)
’23	(0.08)	(0.03)	(0.08)	0.33	0.14
’22	—	—	(0.18)	(0.22)	(0.94)
’22	(0.27)	(0.27)	—	—	(0.94)
’21	—	—	(0.21)	(0.22)	(0.33)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5.60	5.85	2.97	2.32	2.40	4.12	3.59	1.67	2.00	1.82	Analyst estimates 2026–2028 Powerpack
	High	10.51	11.34	9.24	6.05	5.88	31.54	14.77	13.73	3.67	3.24
People
People	Employees	12	14	13	13	12	13	17	15	13	13
	Revenue/emp, $m	0.05	0.18	0.19	0.21	0.23	0.00	0.16	0.09	0.00	0.15
Income, $m
Income, $m	Revenue	1	2	2	3	3	1	3	1	—	2
	Gross margin, %	23.56	92.39	103.51	96.67	100.00	100.00	100.00	100.00	—	0.65
	EBT	(10)	(10)	(13)	(14)	(12)	(12)	(38)	5	(16)	75
	EBT margin, %	(1,502.18)	(410.42)	(519.68)	(519.98)	(424.76)	(1,355.64)	(1,393.41)	379.70	0.00	3,766.20
	Net income	(11)	(10)	(13)	(14)	(12)	(12)	(38)	5	(19)	64
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.05	0.18	0.16	0.15	0.13	0.02	0.07	0.03	0.00	0.05
	Earnings	(0.87)	(0.79)	(0.86)	(0.82)	(0.56)	(0.33)	(0.94)	0.14	(0.48)	1.53
	Cash flow	0.37	(0.44)	(0.98)	(0.74)	(0.61)	(0.30)	(0.72)	(0.26)	(0.21)	(0.22)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	(0.01)	(0.01)	0.00	0.00
	Free cash flow	0.37	(0.44)	(0.99)	(0.74)	(0.61)	(0.30)	(0.73)	(0.26)	(0.21)	(0.22)
	Book value	2.07	1.45	2.09	1.11	1.60	4.49	3.88	4.04	3.56	4.82
	Shares, m	13	13	15	17	21	37	39	40	41	41
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	17.50	—	1.88
	P/S	0.00	46.87	30.08	20.79	26.44	579.21	178.90	36.54	—	29.35
	P/B	3.48	5.98	2.37	2.90	2.18	3.18	3.20	0.61	—	0.59
	EV/Sales	0.00	38.67	17.64	8.85	11.72	419.34	121.29	(23.41)	—	(1.96)
	EV/FCF	249.95	(11.67)	(1.58)	(0.89)	(1.25)	78.17	(11.55)	6.00	—	0.86
Cash, $m
Cash, $m	Operating cash flow	5	(6)	(15)	(13)	(12)	(11)	(28)	(10)	(8)	(9)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	5	(6)	(15)	(13)	(13)	(11)	(28)	(11)	(8)	(9)
Balance, $m
Balance, $m	Working capital	28	15	26	28	36	141	151	109	138	114
	Total debt	—	—	—	—	0	1	1	—	—	—
	Net debt	(31)	(20)	(30)	(32)	(40)	(146)	(156)	(162)	(142)	(126)
	Shareholders’ equity	26	19	31	19	33	167	151	163	145	200
Returns, %
Returns, %	ROA	(31.70)	(25.70)	(29.56)	(34.99)	(29.03)	(7.63)	(22.62)	2.89	(10.14)	32.76
	ROIC	0.00	0.00	(1,302.68)	0.00	0.00	(37.89)	0.00	(1,164.97)	(233.78)	(12.77)
	ROE	(42.98)	(46.14)	(50.55)	(56.85)	(44.04)	(8.24)	(24.14)	3.52	(12.37)	36.65

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025 · fundamentals updated 28 Sep 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ELDN Eledon Pharmaceuticals, Inc.	$184.5M	— (loss-making)	—	—	n/m	−28.02% (below 0%: shrinking)	0.00%	0.00%	Compare
ACOG Alpha Cognition Inc.	$184.0M	— (loss-making)	—	+267.56% (above 0%: growing)	n/m	−109.25% (below 0%: shrinking)	94.80%	(127.29%)	Compare
BCYC Bicycle Therapeutics PLC Sponsored ADR	$181.4M	— (loss-making)	— (loss-making)	−78.46% (below 0%: shrinking)	n/m	+31.95% (above 0%: growing)	100.00%	(8,673.93%)	Compare
PEPG PepGen, Inc.	$175.2M	— (loss-making)	—	—	n/m	+33.02% (above 0%: growing)	0.00%	0.00%	Compare
ORMP Oramed Pharmaceuticals Inc.	$173.9M	1.0×	— (loss-making)	+193.26% (above 0%: growing)	+493.75% (above 0%: growing)	+94.29% (above 0%: growing)	0.65%	0.00%
WHWK Whitehawk Therapeutics, Inc.	$173.3M	— (loss-making)	— (loss-making)	+33.48% (above 0%: growing)	n/m	+72.57% (above 0%: growing)	89.36%	0.00%	Compare
DTIL Precision BioSciences, Inc.	$170.3M	— (loss-making)	— (loss-making)	+37,272.41% (above 0%: growing)	n/m	+33.73% (above 0%: growing)	100.00%	0.00%	Compare
CHRS Coherus Oncology, Inc.	$165.3M	— (loss-making)	— (loss-making)	+39.53% (above 0%: growing)	n/m	−33.15% (below 0%: shrinking)	70.35%	(225.98%)	Compare
IPHA Innate Pharma S.A. Sponsored ADR	$165.3M	— (loss-making)	—	+246.29% (above 0%: growing)	+106.08% (above 0%: growing)	−929.03% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$174.3M	—	—	+142.91%	—	+1.97%	79.86%	0.00%

All 614 Biotechnology stocks →

Oramed Pharmaceuticals Inc. (ORMP) key facts

Oramed Pharmaceuticals Inc. (ORMP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ORMP traded at $4.07, a market capitalization of $173.9 million.
Oramed Pharmaceuticals Inc. pays an annual dividend of $0.25 per share, a yield of 6.14%, with a payout ratio of 6.07%.
Return on equity was 36.7% and debt-to-equity 0.00.
Its Altman Z-score is 1.91 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 28, 2026.